Tag Archive for: oncology

Mestag Therapeutics Selected to Present Targeted LTBR Agonist MST‑0312 in Late‑Breaking Session at AACR Annual Meeting

/in

— MST-0312 is a FAP-targeted lymphotoxin beta receptor (LTBR) agonist bispecific antibody designed to induce tertiary lymphoid structures for the treatment of solid tumors Cambridge, UK, April 14, 2026 – Mestag Therapeutics, a biotech company harnessing fibroblast immunology to develop impactful treatments for patients with cancer and inflammatory disease, announced today that it has been […]

Read more

Laigo Bio completes final close of oversubscribed seed financing of €17 million co-led by Biovance Capital and Kurma Partners to advance oncology and auto-immunity programs

/in

Additional funding of €4m from new co-lead investor Biovance Capital, and €1.5m from existing co-lead Kurma Partners, to reach a total of €5.5m. Funds will be used to further develop Laigo’s SureTACs™ targeted protein degradation candidates in oncology and auto-immunity. UTRECHT, the Netherlands – 23 March 2026 – Laigo Bio (“Laigo”), a biotech company pioneering […]

Read more

Oncoinvent secures new patent expanding protection for Radspherin®

/in

First patent from a new patent family granted in China, strengthening the long‑term intellectual property protection for the Company’s lead product candidate Oslo, Norway, 19 March 2026: Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces […]

Read more

Mestag Therapeutics Announces $40 Million Financing and Appoints Chief Medical Officer and Chief Development Officer in Preparation to Enter the Clinic

/in

— Financing brings total funds committed to date to >$95 million — Proceeds support the STARLYS clinical trial evaluating targeted LTBR agonist MST-0312 in solid tumors, together with platform and pipeline activities in inflammatory diseases — Expands the leadership team with exceptional development executives to propel the clinical advancement of the pipeline Cambridge, UK, March […]

Read more

Poolbeg Pharma plc – Appointment of Dr Adrian Kilcoyne to Scientific Advisory Board

/in

12 March 2026- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the appointment of Dr Adrian Kilcoyne to its Scientific Advisory Board. Dr Kilcoyne brings over 20 years of clinical expertise with strategic drug development leadership, focusing on innovative therapies that address unmet medical needs in oncology […]

Read more
© Optimum Strategic Communications.